Modified Vaccinia Virus Ankara Vaccine Expressing P53
Fallopian Tube Carcinoma
Explore 71 assets in Fallopian Tube Carcinoma →Floatz Rating
B58/100
Confidence
Indicative
Sponsor
City of Hope Medical Center
Modality
vaccine
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03113487CT.gov P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | — | Active Not Recruiting | — | — | — |
NCT02275039CT.gov p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Fallopian Tube Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Modified Vaccinia Virus Ankara Vaccine Expressing P53 (this asset) | City of Hope Medical Center | P2 | B · 58 |
| Carboplatin | Women's Hospital School Of Medicine Zhejiang University | P3 | BBB |
| Cis-Diamminedichloroplatinum Ii | Mayo Clinic | P3 | BB |
| Pembrolizumab | Roswell Park Cancer Institute | P2 | BB |
| Tamoxifen | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | P3 | BB |
| Cyclophosphamide | Mayo Clinic | P2 | BB |
| Olaparib | National Cancer Institute (NCI) | P3 | BB |
| Adriamycin | Brigham and Women's Hospital | P3 | BB |
| Guadecitabine | National Cancer Institute (NCI) | P2 | BB |
+42 more in the Fallopian Tube Carcinoma cohort
Other indications for Modified Vaccinia Virus Ankara Vaccine Expressing P53
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Primary Peritoneal Carcinoma | — | P2 | B · 60 |
| Ovarian Carcinoma | — | P2 | B · 60 |
| Gastric Cancer | — | P1 | CC · 47 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Modified Vaccinia Virus Ankara Vaccine Expressing P53 in Fallopian Tube Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/modified-vaccinia-virus-ankara-vaccine-expressing-p53-fallopian-tube-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →